Fact CheckerSign in

NCT05531591CompletedPhase 4

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)

Source: ClinicalTrials.gov · Last updated 25 Nov 2024

Brief summary (registry, in English)

The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
87 (actual)
First submitted
19 Aug 2022
Start date
1 Aug 2019
Primary completion date
31 Jul 2024
Lead sponsor
Centre for Addiction and Mental Health
Diseases
Depression
NCT number
NCT05531591

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 87
  • From 1 Aug 2019 to the primary completion date, 31 Jul 2024
  • 4 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Dementia; patients screened out due to possible dementia will be referred to a local Memory Clinic or back to their clinician for evaluation to clarify the presence or absence of dementia.
  • Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.
  • High risk for suicide (e.g. active Suicidal ideations (SI) and or current/recent intent or plan)). Urgent psychiatric referral will be made in these cases.
  • Non-correctable, clinically significant sensory impairment (e.g., cannot hear well enough to cooperate with interview).
  • Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management.
  • Moderate to severe substance or alcohol use disorder, as determined by study physician.
  • Seizure disorder.
  • Parkinson's Disease

Who the study is looking for

  • Men and women aged 60 and older, with approximately equal proportions aged 60-70 and 70+.
  • Current Major Depressive Disorder (MDD), single or recurrent, as diagnosed by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
  • Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length (approximately 12 weeks).
  • PHQ-9 score of 10 or higher.

Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre for Addiction and Mental Health
Coordinator of this site? Confirm its status
TorontoCanadaUnknown status
UCLA Late-Life Mood, Stress, and Wellness Research Program
Coordinator of this site? Confirm its status
Los AngelesUnited StatesUnknown status
Columbia University Adult and Late Life Depression Clinic
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Washington University School of Medicine Healthy Mind Lab
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.